{
    "ticker": "SEEL",
    "name": "Seelos Therapeutics, Inc.",
    "description": "Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neuropsychiatric and neurodegenerative disorders. Founded in 2016, Seelos aims to address unmet medical needs in indications such as depression, post-traumatic stress disorder (PTSD), and other central nervous system (CNS) diseases. The company is advancing a diverse pipeline of drug candidates, including SLS-002, a nasal spray formulation of ketamine for treatment-resistant depression, and SLS-005, which targets the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative conditions. Seelos is committed to leveraging innovative science and clinical development to bring new treatments to market, with a strong focus on conducting rigorous clinical trials to validate the efficacy and safety of its drug candidates. The company collaborates with leading academic institutions and research organizations to enhance its research efforts and expedite the development process. Seelos Therapeutics is dedicated to improving the quality of life for individuals suffering from debilitating mental health conditions and neurodegenerative diseases through its therapeutic advancements.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York City, New York, USA",
    "founded": "2016",
    "website": "https://www.seelostherapeutics.com",
    "ceo": "Raj Mehra",
    "social_media": {
        "twitter": "https://twitter.com/seelostherapeutic",
        "linkedin": "https://www.linkedin.com/company/seelostherapeutics/"
    },
    "investor_relations": "https://ir.seelostherapeutics.com",
    "key_executives": [
        {
            "name": "Raj Mehra",
            "position": "CEO"
        },
        {
            "name": "Michael P. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Neuropsychiatric Disorders",
            "products": [
                "SLS-002",
                "SLS-005"
            ]
        }
    ],
    "seo": {
        "meta_title": "Seelos Therapeutics, Inc. | Innovative Therapeutics for CNS Disorders",
        "meta_description": "Explore Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company committed to developing innovative treatments for neuropsychiatric and neurodegenerative disorders.",
        "keywords": [
            "Seelos",
            "Biopharmaceuticals",
            "CNS Disorders",
            "Depression",
            "PTSD",
            "ALS"
        ]
    },
    "faq": [
        {
            "question": "What is Seelos Therapeutics focused on?",
            "answer": "Seelos Therapeutics focuses on developing therapeutics for neuropsychiatric and neurodegenerative disorders."
        },
        {
            "question": "Who is the CEO of Seelos Therapeutics?",
            "answer": "Raj Mehra is the CEO of Seelos Therapeutics, Inc."
        },
        {
            "question": "Where is Seelos Therapeutics headquartered?",
            "answer": "Seelos Therapeutics is headquartered in New York City, New York, USA."
        },
        {
            "question": "What are Seelos's main products?",
            "answer": "Seelos's main products include SLS-002 and SLS-005, targeting depression and ALS, respectively."
        },
        {
            "question": "When was Seelos Therapeutics founded?",
            "answer": "Seelos Therapeutics was founded in 2016."
        }
    ],
    "competitors": [
        "AXSM",
        "SAGE",
        "PTN",
        "VRNA"
    ],
    "related_stocks": [
        "JNJ",
        "MRK",
        "PFE",
        "GILD"
    ]
}